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A series of monoclonal antibodies was used to char-
acterize the nevomelanocytes and the inflammatory in-
filtrate of 11 halo nevi in different stages of resolution, 
employing an immunoperoxidase technique. Three of 
the 11 halo nevi histologically showed signs of mild or 
moderate nevomelanocytic atypia. 
It was found that the vast majority of the nevomelan-
ocytes in halo nevi with a dense inflammatory infiltrate 
markedly expressed HLA-A,B,C antigens, while expres-
sion was not demonstrable in nevocellular nests not 
adjacent to the mononuclear infiltrate. No difference in 
expression of HLA-A,B,C antigens was found between 
the 3 cases with mild or moderate nevomelanocytic 
atypia and the other cases lacking atypia. Expression of 
HLA-DR (la-like) antigens was found on few nevome-
lanocytes in only 2 of 11 lesions. 
The cellular composition of the mononuclear inflam-
matory infiltrate showed a predominance ofT cells (80% 
or more) with a relatively high proportion of cytotoxic/ 
suppressor T cells. Most of the T cells showed signs of 
activation as judged by staining for HLA-DR antigens. 
These results demonstrate that the expression of HLA-
A,B,C antigens on the nevomela-?ocytes and the cellular 
composition of the mononuclear Inflammatory infiltrate 
in halo nevi are very similar to that in malignant mela-
nomas and dysplastic nevi. These findings also indicate 
that the expression of HLA-A,B,C antigens on nevome-
lanocytes is primarily dependent on the presence of T-
cell immune response and not necessarily related to the 
presence of nevomelanocytic atypia. 
Halo nevi (HN) are spontaneously regressing moles which 
develop an enlarging ha lo of depigmentation around t h e dis-
appearing lesion. This phenomenon, which is not at a ll uncom-
mon, is usually seen in children and young adults of either sex 
[1). Histologically most HN are compound nevi without nevo-
melanocytic atypia . In early regressing lesions t here is a dense 
mononuclear inflammatory infiltrate abou t the nevus and in 
later les ions t he nevus cells may show s igns of degeneration, 
which is interpreted as a result of a nevus-directed immune 
response [2] . However, t he pathogenesis of HN is poorly under-
stood. 
In the last decade attempts have been made to further 
investigate the immunologic mechanism of the halo phenome-
non. Evidence for ce llula r and humora l immunity, i.e., antibod-
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ies directed to the cytoplasm of malignant melanoma cells were 
found in the peripheral blood of patients with HN, suggesting 
an antigenic resemblance between nevomelanocytes in HN and 
cutaneous malignant melanoma [3-6]. In 1972 Lewis and Cope-
man postulated that a HN represents the "visualisation of 
rejection of a malignant melanoma, the nevus being a frustrated 
melanoma" [7]. 
Recent studies have shown marked expression of histocom-
patibility antigens (HLA) on nevomelanocytes in malignant 
melanoma and in some dysplastic nevi (DN), but not or only 
slightly on nevomelanocytes in common nevocellular nevi [8] . 
Expression of HLA antigens may be involved in triggering 
cellular immune response against dysplastic or malignant ne-
vomelanocytes. Therefore we have examined the expression of 
HLA antigens on the nevomelanocytic component and the 
composition of the inflammatory infil trate in 11 HN in diffe r-
ent stages of regression. 
MATERIALS AND METHODS 
Patients a.nd Excised Specimens 
Surgical excision specimens of 11 HN were obtained from 11 differ-
ent patients (9 males, 2 females; mean age 25 .2 years). The main 
portion of each specimen was processed for routine histopathologic 
examination. A representative portion of each specimen was snap-
frozen in liquid nitrogen and stored at -70"C for immunohistochemical 
analysis. . 
Clinically (see Table I) , the HN showed different stages of resolutiOn 
with either a pigmented mole (in, 2, 4-6, 8-10), a red papule (#3), or 
a pink residual staining (#10) in the central part of the halo. In one 
patient (#7) the nevus appeared to be totally resolved. In 3 of the 10 
patients (#4-6) the HN showed histologic signs of nevomelanocyt1c 
atypia, i.e ., irregular shape of rete ridges and horizontal extension of 
nevomelanocytic proliferation, nuclear polymorphism with the nuclear 
size of the melanocytes as large as or larger than the nuclei of the 
keratinocytes. In these cases the diagnosis of dysplastic nevus syndrome 
(DNS), fa milial type, based on clinical and histologic criteria [9] had 
been made previously. In one of these patients (#6) 2 superfic1al 
spreading malignant melanomas (maximum tumor thickness according 
to Breslow, 0.36 and 0.54 mm) had been excised 1 and 2 years, 
respectively, prior to the present investigations. 
Clinical signs of vitiligo were observed in 2 patients (#5 and 9). The 
clinical data of the patients are summarized in Table I. 
I rnmunohistochemical Examination 
The nevomelanocytes in the HN were characterized by monoclonal 
antibodies against backbone determinants of class I (HLA-A,B,C, 
Bethesda Research Laboratories Inc.) and class II (HLA-DR, Ia- like, 
Bethesda Research Laboratories Inc.) major histocompatibility com-
plex (MHC) antigens, and the monoclonal antibody 225.288 (provided 
by Dr. S. Ferrone, Department of Microbiology and Immunology, New 
York Medical College, Valhalla, New York), which reacts with ant igens 
present on nevomelanocytes in nevocellular nevi and malignant mela-
nomas [10]. This di ffe rentiation marker was used in serial sections 
with the anti-MHC antibodies in order to distinguish between nevo-
melanocytes and cells of the mononuclear inflammatory infiltrate in 
difficult cases. · 
For characterization of the mononuclear inflammatory infiltrate a 
panel of monoclonal antibodies with well-defined specificities was used. 
These included Leu-1 (pan -T-cell antiserum), Leu-2a (suppressor/ 
cytotoxic T cell subset) , and Leu-3a (helper/inducer T-cell subset; 
weak int racytoplasmic staining of macrophages), purchased from Bee-
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TABLE I. Clinical data of patients studted 
Patient Sex Age Site 
1 K F 15 Back 
2 VI M 18 Back 
3 Ko M 12 Back 
4 vVe M 15 Back 
5 Ke F 19 Back 
6 vdB M 34 Back 
7 M M 56 Back 
8 Veri M 31 Abdomen 
9 vE M 23 Side 
10 vA M 32 Back 
11 Ba M 22 Back 
DNS = Dysplastic nevus syndrome. 
ton & Dickinson , Sunnyva le, California, HLA-DR antiserum (Bethesda 
Research Laboratories lnc.) which reacts with class II molecules pres-
ent on B lymphocytes, monocytes/macrophages, and activated T ce lls. 
In addition , OKM l (monocytes, granulocytes) and OKT6 (reactive 
with 70% of human thymocytes, and Langerhans and/or related cells) 
were used. These antibodies were obtained from Ortho Pharmaceuticals 
Ltd. Rabbit antisera against kappa and lambda light chains (Dakopatts, 
Denmark) were used for demonstration of B cells. 
For in situ demonstration of antigens reactive with these antibodies, 
an indirect immunoperox idase technique was used with hematoxylin 
counterstaining, as previously desc ribed [8]. Diaminobenzidine was 
replaced by arninoethylca rbazol, since the red reaction product of the 




In all lesions but one, remnants of the original nevocellular 
nevus were found to a variab le extent; in 7 of these a compound 
nevus was present. fn 1 lesion ( ~9 ) on ly dermal nevus nests 
were observed and in 1 lesion ( ~ 10) no nevomelanocytes could 
be identitied. In patient ~7, with the clinical appearance of a 
totally resolved HN, scattered nevomelanocytes were identified 
in the dermis amid mononuclear inflammatory cells. 
In 8 HN ( ~ 1 -3, 7- 11) no s igns of architectural or cytologic 
atypia were found. Histologically the 3 remaining cases (~4-6) 
were classified as DN, showing mild to moderate atypia of 
nevomelanocytes, fibrosis, accumulation of melanophages, and 
signs of neovascularization. The corresponding patients had 
the famili al DNS. In 1 of these patients (~ 6) atypia was 
observed only loca lly in a junctional nest with adjacent inflam-
matory infiltrate, whi le other nests did not show either atypia 
or inflammatory in fi lt rate. 
A moderate to ma rked degree of mononuclear inflammatory 
infiltrate was present in the lesions of patients ~1-8 . The 
inflammatory infiltrate was main ly located in a bandlike con-
figuration beneath the nevocellular cell s in the middermis, and 
in pat ients ~1 -5 and 7 a lso amid nevoce llular nevus cells in 
the upper dermis. As mentioned before in the lesion of patient 
~6 inflammatory cells were only found adjacent to a junctional 
nevus nest with cytologic atyp ia. The infiltrate was composed 
predom inantly of lymphocytes; plasma cells, histiocytes, and 
mast cell s were sca rce and eosinophils and granulocytes were 
abse nt. 
The inllammatory mononuclear infiltrate was minimal in t he 
lesions of patients ~9-11. It was found in the superfic ial dermis 
amid melanophages and remnants of the nevocellular nevus , 
except in patient )1)!10 where no nevocellular cel ls could be 
demonstrated. 
Immunohistochemical Findings 
In the HN with a ma rked inflammatory infi ltrate (~ l-8) the 
vast majority of t he nevomelanocytes strongly expressed HLA-
A,B,C anti ge ns (see Fig 3) . fn 1 of these cases (~6) both posit ive 




Pigmented center DNS 
Pigmented center DNS + vitiligo 
Pigmented center DNS (+multiple PCMM) 
Totally resolved 
Pigmented center 
Pigmented center Viti ligo 
Pink center 
Pigmented center 
FIG 1. Halo nevus. Adjacent to epidermis (e) and junctional nests 
of nevomelanocytes (n) there is a mononuclear inflammatory in!iltrate 
(i). Frozen section, H & E, X 100. 
and negative nests corresponding with the presence or absence 
of an adjacent inflammatory infiltrate, respectively, were ob-
served. Staining for anti HLA-A,B,C antigens on nevomelan-
ocyles in HN with a scarce mononuclear infiltrate was weak 
(~11) or completely absent ( ~9). In 2 cases (~3 and 4) expres-
sion of OR-antigens (Ia-like) was foca lly observed in nevome-
lanocytes. In both lesions staining was restricted to individual 
cells or small groups of nevomelanocytes scattered amid a dense 
mononuclear infiltrate. Staining of intact nevus nests with anti 
OR-monoclonal antibodies was not observed. In Figs 1 to 5 
serial sections of patient ~1 are shown stained with H & E (Fig 
1), with a nevomelanocyte associated antibody (225.28S, Fig 
2), with anti-HLA-A,B,C antibody (Fig 3), with anti-HLA-DR 
antibody (Fig 4), and with anti-Leu-1 antibody (Fig 5). 
Immunohistochemical analysis of the mononuclear infil-
trates showed a similar pattern in all les ions. The large majority 
of the infiltrate cells (80% or more) were reactive with the pan-
T antiserum Leu-1. In addition, small clusters or individual 
dendritic OKT6+ Langerhans and/or related ce lls were found 
scattered in the lymphocytic infiltrate, in particular in the 
subep idermal zone. B cells and cells reactive with OKM1 anti-
se rum were scarce or absent. Regarding the distribution ofT-
ce \1 subpopulations, approximately equal numbers of Leu-3a+ 
(helper/inducer T-cell phenotype) and Leu-2a+ T cells (cyto-
toxic/suppressor T -cell phenotype) were observed in most 
cases. The Leu-3a:Leu-2a ratios varied between 3:1 and 2:3 
(Table II). Examination of serial sections stained with anti-
HLA-DR and Leu-1 antibodies showed considerable numbers 
of HLA -DW T cel ls (Figs 4, 5). 
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DISCUSSION 
Evidence for a marked cellular and humoral immune re-
sponse is found in both HN and primary cutaneous melanomas 
(PCMM) . Histologically both conditions show a dense mono-
nuclear inflammatory infiltrate in close association with the 
nevomelanocytic component of the lesion. Cellular cytotoxicity 
against melanoma cells [5 ,6] and melanoma-associated anti-
bodies [3] have been demo nst rated in sera of patients with 
regressing HN and recently also in the sera of patients with 
vitiligo [11 ,12 ]. It is inte resting that the occurrence of either 
',! • . ·, ~ ~~-
. ..t .JI.. 
FIG 2. Ha lo nevus sta ined with nevomela nocyte associated anti-
body (225.28S). The junctional nevus nests (n) can be distinguished 
from the epidermis (e) and the mononuclear inflammatory infiltrate 
(i). Serial section to Fig 1, coun terstained with hematoxylin, X 100. 
FIG 3. Ha lo nevus stained wi th anti- HLA-A,B,C antibody. Epider-
mis (e) , nevus nests (n) and mo nonuclear inflammatory infiltrate (i) 
stain with s imila r intensity. Seria l section to Figs 1 and 2, counter-
stained with hematoxylin, X 120. 
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vitiligo or HN has been reported in association with malignant 
melanoma [13] and is prognostically a good sign [14]. 
In the present study we have examined the composition of 
the mononuclear inflammatory infiltrate as well as the in situ 
distribution of MHC antigens HLA-A,B,C and HLA-DR on 
nevomelanocytes of 11 halo nevi, because of their significance 
in the regulation of the cellular immune response [15 ,16]. 
The composition of the inflammatory infiltrate was very 
consistent, showing a predominance of (activated) T cells (80% 
FIG 4. Halo nevus stained with anti-HLA-DR antibody, showing 
considerable numbers of HLA-DR+ T cells. e = Epidermis, n = nevus, 
and i = mononuclear inflammatory infiltrate. Seria l section to Figs 1-
3, counterstained with hematoxylin , X 100. 
FIG 5. Halo nevus stained with anti-Leu·1 ant ibody. In the central 
portion of t he photograph t he infiltrate (i) conta ins a considerable 
number of reacting cells. e = Epidermis, n = nevus. Serial section to 
Figs 1- 4, counterstained with hematoxylin, X 100. 
TABLE II. Results of immuohistochemical analys~s of lesions studied 
Nature of 
Degree of inflammatory infi ltrate• inflarn ma- HLA·A,B,C HLA-DR 
tory infil · 
Patient Nevomelanocytic trate atypian 
Surrounding In the Percentage of Intensity Percentage of Intensity 
ncvomelanocytic nevome lanocytic Leu·3:Leu·2 nevome lanocytes of nevomelanocytes of 
lesion les ion stained sta inin gc stained staining( 
1 3+ 3+ 3:2 100 3+ 0 
2 3+ 3+ 3:2 100 3+ 0 
3 3+ 1+ 2:3 100 3+ 5 2+ 
4 2+ 3+ 1+ 1:1 100 3+ 5 3+ 
5 1+ 2+ 1+ 3:2 100 3+ 0 
6 2+ 2+ 3:2 20 2+ 0 
(foca lly) (foca lly) (focally) 
7 2+ 1+ 3:2 100 3+ N.l. N.J . 
8 1+ 3:1 80 2+ 0 
9 ± N.I. 0 0 
10 N.A. ± N.J. N.A. N.A. 0 
11 ± N.I. 100 1+ 0 
"Scored as:- (absent) , 1+ (mi ld), 2+ (moderate), 3+ (marked) (see Materials and Methods). 
b Scored as: - (absent) , ± (scarce), 1 + (slight foca l, perivenu la r) , 2+ (moderate aggregate- like), 3+ (extensive bandlike). 
c Scored as: - (absent) , 1 + (mi ld staining), 2+ (bright sta ining, but less than epidermis), 3+ (same intensity of staining as epidermis) . 
N .I. = Not interp retable. 
N.A. =Not applicable. 
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TABLE II I. Relation between the expression of H LA antigens and the 























+ = Present; +/- = usually present; -/+ = usually absent; - = 
absent. 
or more) with a relative increase of Leu -2a+, probably cytotox ic, 
T cells, and few or noB cell s and OKMl + cells. Recent studies 
on the cel lular composition of t he mononuclear inflammatory 
infi ltrate in PCMM have demonstrated very similar results 
[17- 20). 
In t he present study it was found that in HN with an 
intensive inflammatory infiltrate the large majority of nevo-
melanocytes strongly expressed HLA-A,B,C antigens. On t he 
other hand, nests of nevomelanocytes not adjacent to the 
inflammatory infiltrate did not show HLA-A,B,C expression. 
Previous studies have demonstrated the presence of HLA-
A,B,C antigens on nevomelanocytes in PCMM and DN but 
not, or in low amounts, in acquired nevocellular nevi [8,21] . It 
was therefore suggested that the expression of HLA-A,B,C on 
nevomelanocytes is related either to atypia of nevomelanocytes 
or to the presence of adjacent mononuclear cell infiltrate , both 
conditions being present in PCMM and DN but not in common 
nevocellular nevi [8]. 
However, our observations in HN, most of which did not 
show cellular atypia, suggest that the expression of HLA-A,B,C 
antigens by nevomelanocytes is not necessarily related to the 
presence of nevomelanocytic atypia, but primarily correlates 
wi t h the presence of an adjacent inflammatory infiltrate (Table 
III). 
The presence of HLA-A,B,C on the nevomelanocytes of HN 
has great functional significance, since expression of these 
molecules is necessary for target recognition by specific cyto-
toxic T ce lls [22]. The relative ly high number of Leu-2a+ T 
cells supports the view that the inflammatory infiltrate is 
elicited by the HLA-A,B,C antigens present on the nevomelan-
ocytes. This cytotox ic inflammatory infiltrate is likely to be 
responsible for the complete regression observed in HN. On 
the other hand HLA-A,B,C may be induced by -y-interferon 
[23] derived from (Leu-3a+!) T ce ll s but th is construction does 
not explain the presence of the infiltrate. 
Shedding of antigens from lymphocytes as an explanation of 
expression of HLA-A,B,C antigens by nevomelanocytes is un-
likely because of the cytoplasmic staining pattern. 
Staining with HLA-DR antibody revealed only small num-
bers of scattered positive nevomelanocytic cells in 2 of 10 
lesions. It is remarkable that HLA-DR-positive nevomelano-
cytic cells were found only in areas with T lymphocytes infil-
trating nevoid nests, supporting the possib ility of induction of 
HLA-DR expression on nevomelanocytes by T lymphocytes in 
close proximity. Recent studies in PCMM have demonstrated 
that these HLA-DR antigens are actively synthesized by the 
malignant nevomelanocytes themselves, rather than passively 
absorbed from other HLA-DR+ ce ll s [24]. 
The apparent identical distribution of HLA-A,B,C antigens 
and the composition of the mononuclear inflammatory infil-
trate in HN, DN, and PCMM suggests a very s imilar immune 
response operative in these conditions, and provides further 
support for a close antigenic resemblance between nevomelan-
ocytes in HN and those in PCMM. Yet, complete regression is 
obse rved in HN, but occurs in only 4- 8% of the pat ients with 
PCMM [25]. This different biologic behavior in PCMM might 
Vol. 85, No.1 
be the result of selection of melanoma cell clones with inappro-
priate expression of MHC or other relevant antigens, thereby 
evading cytotoxicity, and allowing a vertical growth phase and 
metastases [26,27]. The nature of the antigenic modulation of 
nevomelanocytes that is apparently associated with marked 
HLA-A,B,C expression in PCMM and HN, however, remains 
to be established. 
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